TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8198761
Drug: Plain tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablet (reference drug)
Study: 3798537
Drug: Russell's viper
Normalized name: Russell's viper venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russell's viper venoid (0.5 ml subcutaneous injection followed by two booster injections at four-week intervals)
Study: 23197780
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) with insulin
Study: 23197780
Drug: Akt inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Akt inhibitor (wortmannin)
Study: 8145004
Drug: Hemofer (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemofer (2 tablets = 18 mg iron/day)
Study: 8145004
Drug: Erco-Fer (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erco-Fer (1 tablet = 60 mg iron/day)
Study: 1948094
Drug: Defibrotide 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 400 mg b.i.d. for 6 months
Study: 1948094
Drug: Defibrotide 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 800 mg o.d. for 6 months
Study: 1948094
Drug: Defibrotide 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 800 mg
Study: 29653
Drug: Trimepranol (10-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimepranol (10-14 mg/twice daily)
Study: 29653
Drug: Chlorthalidone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (50 mg every second day)
Study: 29653
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trimepranol and chlorthalidone
Study: 26335089
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives of £15 (US $23) for each long-acting injectable antipsychotic (LAI) received.
Study: 7880938
Drug: Arginine (ARG)
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine (ARG) 30 g infused over 30 min starting at 0 min
Study: 7880938
Drug: Pyridostigmine (PD)
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine (PD) 120 mg orally, 60 min before GHRH administration
Study: 19512981
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily
Study: 16943402
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (Control)
Study: 11214707
Drug: DDD pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDD pacing or oral theophylline
Study: 9598259
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (25 ml.kg-1)
Study: 9598259
Drug: Dextran 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 3% (10 ml.kg-1)
Study: 3170960
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (0.27 mmol/kg body weight)
Study: 31570296
Drug: Dichlorphenamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichlorphenamide (50 mg or 100 mg daily for adolescents)
Study: 31570296
Drug: Dichlorphenamide (105.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichlorphenamide (105.7 mg mean daily for adults)
Study: 25494864
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity allele score (GS‐InSens)
Study: 25494864
Drug: Insulin secretion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin secretion allele score (GS‐InSec)
Study: 23243248
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control diet (0.304 g of monocalcium phosphate per kg)
Study: 21884956
Drug: Ingesting ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting ≥1 of prescribed hypertension medications at bedtime
Study: 15311218
Drug: Chitosan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (3 g/day)
Study: 9369265
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 (30 mg)
Study: 2417834
Drug: 5% plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% plasma protein solution
Study: 27178047
Drug: fasiglifam 25
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam 25 mg once daily
Study: 27178047
Drug: fasiglifam 50
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam 50 mg once daily
Study: 27178047
Drug: fasiglifam monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam monotherapy
Study: 27178047
Drug: sulphonylurea combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulphonylurea combination therapy
Study: 27178047
Drug: fasiglifam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: fasiglifam (both doses)
Study: 24731434
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (high dose left prefrontal repetitive transcranial magnetic stimulation)
Study: 23005919
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI with valved spacer
Study: 23005919
Drug: Albuterol MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI with non-valved spacer
Study: 20473771
Drug: Trigeminal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigeminal block with 0.8‐mL lidocaine 2%
Study: 20473771
Drug: Deep sedation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sedation and trigeminal injection of 0.8‐mL saline (Control)
Study: 10411034
Drug: Sequential BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential BCG and epirubicin (group 1)
Study: 1883257
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d) for 2 weeks
Study: 1883257
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at neuroleptic threshold dosages (mean, 3.4 +/- 2.3 mg/d) for 2 weeks
Study: 1883257
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at higher dosages (mean, 11.6 +/- 4.7 mg/d)
Study: 6870221
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of metronidazole (500 mg over 20 min)
Study: 6870221
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of tinidazole (500 mg over 20 min)
Study: 6870221
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of metronidazole (500 mg)
Study: 6870221
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tinidazole (500 mg)
Study: 6870221
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of metronidazole (1,000 mg)
Study: 6870221
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of tinidazole (1,000 mg)
Study: 6870221
Drug: Intravaginal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal administration of metronidazole (500 mg)
Study: 6870221
Drug: Intravaginal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal administration of tinidazole (500 mg)
Study: 6870221
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of either drug
Study: 6870221
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of either drug
Study: 6870221
Drug: Intravaginal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal administration of either drug
Study: 29894202
Drug: Insulin intervention
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin intervention during dual clamp in MHD patients
Study: 29894202
Drug: Insulin intervention
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin intervention during dual clamp in controls
Study: 20078686
Drug: C-HAT (currently
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-HAT (currently on heroin-assisted treatment)
Study: 15845709
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine plus IV morphine via patient‐controlled analgesia (ITM+PCA group)
Study: 15845709
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine via patient‐controlled analgesia (PCA‐only group)
Study: 10354965
Drug: Pleconaril oral
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril oral capsules (50 to 1000 mg)
Study: 8550116
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg per day)
Study: 8550116
Drug: Nifedipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10-20 mg per day)
Study: 1769321
Drug: L-sulpiride 25
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride 25 mg t.i.v./day, p.o. for 30 days
Study: 6175830
Drug: Prazosin 2
Normalized name: prazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 2 mg
Study: 6175830
Drug: Trimazosin 200
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin 200 mg
Study: 6175830
Drug: UK-33,274 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-33,274 4 mg
Study: 31091866
Drug: Formulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation of metabolites from both bacterial strains
Study: 25234481
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment group (control)
Study: 23968815
Drug: METH (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (30 mg)
Study: 23968815
Drug: METH (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: METH (0 mg)
Study: 19689661
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg loading dose of clopidogrel followed by 150 mg daily for 1 week prior to angiography
Study: 19689661
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg loading dose of clopidogrel
Study: 17804841
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 U weekly for a maximum of 3 weeks)
Study: 15028824
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (fluorouracil)
Study: 15028824
Drug: Both chemoradiotherapy
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both chemoradiotherapy and chemotherapy
Study: 9833860
Drug: Zidovudine, didanosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, didanosine, and nevirapine combination therapy
Study: 9833860
Drug: More sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: More sensitive assay with a lower quantification limit of 20 copies/ml
Study: 2145232
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus + 2.5 micrograms/kg/minute infusion
Study: 2145232
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus + 5.0 micrograms/kg/minute infusion
Study: 2145232
Drug: Enoximone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 0.5 mg/kg bolus + 10.0 micrograms/kg/minute infusion
Study: 2145232
Drug: Enoximone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone 5.0 micrograms/kg/minute infusion without bolus
Study: 2145232
Drug: Enoximone infusion
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone infusion at rates greater than 5.0 micrograms/kg/minute
Study: 2145232
Drug: Enoximone infusion
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone infusion
Study: 6994778
Drug: Guanfacine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (2 to 6 mg daily)
Study: 6994778
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 to 0.9 mg daily)
Study: 28086164
Drug: Adjunctive lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive lacosamide
Study: 28686778
Drug: 2% SA
Normalized name: Care Touch Alcohol 62% Sanitizing Hand Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% SA topical gel enriched with botanicals
Study: 25490610
Drug: 7-day buprenorphine
Normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7-day buprenorphine tapering schedule
Study: 25490610
Drug: 28-day buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day buprenorphine tapering schedule
Study: 23719234
Drug: Colistin sulphate
Normalized name: Colistin sulphate
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colistin sulphate (50 mg 4×/day) and neomycin sulphate (250 mg 4×/day) for 10 days plus nitrofurantoin (100 mg 3×/day) for 5 days
Study: 23719234
Drug: Colistin and
Normalized name: Colistin and hydrocortisone and neomycin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin and neomycin treatment
Study: 17719313
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg, TID for 6 months
Study: 17719313
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual drug therapy) for 6 months
Study: 9726717
Drug: Beclomethasone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (mean daily dose, 640 microg)
Study: 2721103
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of disulfiram daily
Study: 2721103
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of disulfiram daily
Study: 6368445
Drug: Antacid mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid mixture
Study: 783029
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by small quantities of antacids
Study: 28471731
Drug: Ashwagandha root
Normalized name: ashwagandha root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha root extract (300mg twice daily)
Study: 23810269
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activity (DPA) assessment using DigiWalker SW-200
Study: 11422002
Drug: Itraconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (400 mg on the first day then 200 mg day‐1 for 3 days)
Study: 9288700
Drug: Thyroid stimulating
Normalized name: Thyroid stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid stimulating hormone and triiodothyronine
Study: 8391792
Drug: Subcutaneous enoxaparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin, given twice daily
Study: 8391792
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous unfractionated heparin (UFH), adjusted-dose
Study: 27362245
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero Cell Rabies Vaccine (PVRV), n = 702, 5-dose regimen
Study: 27362245
Drug: Purified Chick
Normalized name: rabies vaccine, purified chick embryo cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Chick Embryo Cell Vaccine (PCECV), n = 747, 5-dose regimen
Study: 27362245
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both vaccines
Study: 25224610
Drug: ARV-based prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV-based prevention (tenofovir gel, oral tenofovir, oral Truvada)
Study: 22926209
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (160 U, 320 U, or 640 U antigen per dose)
Study: 22926209
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (2 doses)
Study: 22926209
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (1 dose)
Study: 16000352
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (5 to 10 ppm)
Study: 8891887
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg aspirin once daily for 2 weeks
Study: 8891887
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg ticlopidine twice daily for 2 weeks
Study: 1671940
Drug: HIVAC‐1e vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVAC‐1e vaccine
Study: 6147412
Drug: Bromazepam 3
Normalized name: bromazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 3 mg, three times daily
Study: 6147412
Drug: Bromazepam 6
Normalized name: bromazepam 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam 6 mg, three times daily
Study: 6147412
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg, three times daily
Study: 12660517
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) therapy
Study: 21135365
Drug: Aspirin 162
Normalized name: aspirin 162 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 162 mg plus clopidogrel 75 mg daily
Study: 21135365
Drug: Aspirin 162
Normalized name: aspirin 162 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 162 mg plus placebo daily
Study: 9081959
Drug: Pralidoxime (PAM)
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pralidoxime (PAM) infusion, 1 gm 8 hourly for four days (total 12 gms)
Study: 9081959
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of Pralidoxime (PAM), 1 gm immediately after admission
Study: 2528826
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy with lidocaine
Study: 2528826
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy with lidocaine combined with a steroid
Study: 2528826
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vapocoolant spray with acupressure
Study: 2528826
Drug: Therapy without
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy without injected medication
Study: 1067749
Drug: Zinc therapy
Normalized name: PYRITHIONE ZINC 2 g in 100 g TOPICAL SOAP [Zinc Therapy]
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc therapy (90 mg Zn2+ daily as zinc sulphate by mouth during the latter part of pregnancy)
Study: 1067749
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no zinc therapy)
Study: 28383410
Drug: Significant Histological
Normalized name: Entamoeba histolytica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Significant Histological Model (SHM) scoring system using serum AST, PLT, ALB, and HBV DNA (log10 IU/mL) levels
Study: 23980351
Drug: Yiqi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huoxue Recipe (YHR) combined with Western drugs
Study: 16701188
Drug: Preincisional (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional (10 mL) and postoperative (10 mL) wound infiltration of 0.5% bupivacaine (group 1)
Study: 16701188
Drug: Preincisional bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional bupivacaine (10 mL) and postoperative infiltration of placebo (normal saline solution) (group 2)
Study: 16701188
Drug: Preincisional placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional placebo (10 mL) and postoperative bupivacaine (10 mL) (group 3)
Study: 16701188
Drug: Preincisional (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincisional (10 mL) and postoperative infiltration of placebo (10 mL) (group 4)
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours) for 14 days
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours) for 7 days
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours) for 6 days
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours) for 13 days
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours) for 7 days (discontinued)
Study: 8163717
Drug: Moricizine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moricizine (250 mg every 8 hours)
Study: 29724590
Drug: PFNA Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFNA Augmentation group
Study: 26271050
Drug: Single-dose ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose ciprofloxacin treatment for nalidixic acid-susceptible strains